Skip to main content
. 2021 Oct 8;52(9):702–713. doi: 10.1159/000519043

Table 2.

Ratio between the mean AAD/6W in each subgroup category and the within-arm mean AAD/6W (FAS)

Parameter DA (comparative) Roxadustat (comparative) Difference p value
ERI
 <1.9 0.739 0.899 0.160 0.203
 ≥1.9–<3.5 0.793 0.917 0.124 0.413
 ≥3.5–<6.8 0.967 0.922 −0.045 0.753
 ≥6.8 1.541 1.219 −0.322 0.085
Hs-CRP by nmol/L cutoff
 <28.57 0.946 0.986 0.040 0.628
 ≥28.57 1.230 1.066 −0.164 0.493
DM
 With 0.838 1.038 0.200 0.020
 Without 1.175 0.959 −0.216 0.120
eGFR by mL/min/1.73m2 cutoff
 <15 1.239 1.048 −0.191 0.192
 ≥15 0.785 0.963 0.178 0.025
Primary disease of CKD
 CGN 1.058 0.955 −0.103 0.640
 DN 0.789 1.049 0.260 0.007
 NS 1.219 0.989 −0.229 0.179
 Other 1.000 0.933 −0.067 0.786
Concomitant ACEi/ARB use
 Yes 0.984 0.995 0.011 0.896
 No 1.080 1.023 −0.057 0.796
GNRI category
 <95.1 1.217 0.986 −0.231 0.274
 ≥95.1–<98.3 1.100 0.898 −0.202 0.263
 ≥98.3–<101.3 0.898 1.044 0.146 0.540
 ≥101.3–<104.2 0.746 1.014 0.269 0.034
 ≥104.2 1.053 1.039 −0.014 0.935
PNI category
 <43.6 1.199 1.054 −0.145 0.415
 ≥43.6–<46.8 1.071 0.941 −0.131 0.486
 ≥46.8–<49.7 0.946 0.974 0.028 0.858
 ≥49.7 0.767 1.018 0.250 0.048

AAD/6W, average allocated dose of roxadustat or DA per administration in the last 6 weeks; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ERI, erythropoiesis-stimulating agent resistance index; FAS, full analysis set; GNRI, geriatric nutritional risk index; PNI, prognostic nutritional index; TSAT, transferrin saturation; DA, darbepoetin alfa; hs-CRP, high-sensitivity C-reactive protein; DM, diabetes mellitus; CGN, chronic glomerular nephritis; DN, diabetic nephropathy; NS, nephrosclerosis.